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Aim: Patients with non-insulin-dependent diabetes mellitus (NIDDM) are at increased 
cardiovascular risk due to an accelerated atherosclerotic process. The present study aimed to 
compare skin microvascular function, pulse wave velocity (PWV), and a variety of hemostatic 
markers of endothelium injury [von Willebrand factor (vWF), plasminogen activator inhibitor-1 
(PAI-1), tissue plasminogen activator (t-PA), tissue factor pathway inhibitor (TFPI), and the 
soluble form of thrombomodulin (s-TM)] in patients with NIDDM.
Methods: 54 patients with NIDDM and 38 sex- and age-matched controls were studied. 
27 diabetics had no overt micro- and/or macrovascular complications, while the remainder 
had either or both. The forearm skin blood ﬂ  ow was assessed by laser-Doppler imaging, which 
allowed the measurement of the response to iontophoretically applied acetylcholine (endothelium-
dependent vasodilation) and sodium nitroprusside (endothelium-independent vasodilation), as 
well as the reactive hyperemia triggered by the transient occlusion of the circulation.
Results: Both endothelial and non-endothelial reactivity were signiﬁ  cantly blunted in diabetics, 
regardless of the presence or the absence of vascular complications. Plasma vWF, TFPI and 
s-TM levels were signiﬁ  cantly increased compared with controls only in patients exhibiting 
vascular complications. Concentrations of t-PA and PAI-1 were signiﬁ  cantly increased in the 
two groups of diabetics versus controls.
Conclusion: In NIDDM, both endothelium-dependent and -independent microvascular skin 
reactivity are impaired, whether or not underlying vascular complications exist. It also appears 
that microvascular endothelial dysfunction is not necessarily associated in NIDDM with 
increased circulating levels of hemostatic markers of endothelial damage known to reﬂ  ect a 
hypercoagulable state.
Keywords: skin microcirculation, iontophoresis, pulse wave velocity, type 2 diabetes, hemostatic 
markers
Introduction
Endothelial cells have a strategic location at the interface between the blood and tissues 
and release a number of autocrine and paracrine substances critically involved in the 
regulation of vascular tone and the local control of ﬂ  ow and hemostasis (Verma and 
Anderson 2002). Insulin resistance and endothelial dysfunction are closely related 
during the development of type 2 diabetes (Caballero 2003; Kim et al 2006). In fact, 
endothelial dysfunction may be at the same time a cause and a consequence of the 
insulin resistance syndrome (Pinkney et al 1997; Wheatcroft et al 2003). Endothelial 
dysfunction and/or damage is associated with an increased cardiovascular risk and 
represents an early feature in the atherosclerotic process (Verma et al 2003; Brunner 
et al 2005).
The incidence of type 2 diabetes (non-insulin-dependent diabetes mellitus, 
NIDDM) is exploding worldwide and it is becoming a prominent burden on health Vascular Health and Risk Management 2008:4(6) 1450
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care (Murray and Lopez 1996; Amos et al 1997). Patients 
with NIDDM incur a high risk of cardiovascular and renal 
complications (Nathan 1993). The present investigation was 
performed to assess whether there is a graded worsening 
in endothelial function and/or damage from non-diabetic 
subjects to patients with NIDDM, regardless of whether 
micro- and/or macrovascular complications are exhibited.
Endothelial function was evaluated using a laser-
Doppler ﬂ  owmeter allowing the measurement of skin blood 
responses to iontophorized acetylcholine (Ach), which 
dilates by releasing nitric oxide (NO) from the endothelium, 
to sodium nitroprusside (SNP), which acts as a NO donor 
directly in vascular smooth muscle cells, and to local heating 
(Anderson 1999; Kubli et al 2000; Golay et al 2004). We 
also measured circulating levels of hemostatic regulatory 
molecules physiologically produced by endothelial cells, 
such as plasminogen activator-1 (PAI-1), von Willebrand 
factor (vWF), tissue plasminogen activator (tPA), free tissue 
factor pathway inhibitor (f-TFPI), and the soluble form of 
thrombomodulin (s-TM) (Cines et al 1998; Morange et al 
2001, 2004). Increased plasma levels of these molecules may 
serve as markers of endothelial dysfunction and/or damage 
(Morange et al 2001; Blann et al 2002; Kato 2002; Kathiresan 
et al 2006). Finally, we determined pulse wave velocity as 
an index of arterial stiffness (Asmar et al 1995).
Methods
Subjects
We recruited 54 consecutive patients with type 2 diabetes 
referred to our outpatient clinic. The diagnosis of type 
2 diabetes was based on the 1998 WHO criteria (Alberti and 
Zimmet 1998). Thirty-eight healthy subjects matched for 
gender and age served as controls. The latter had all a fasting 
glycemia 6.1 mmol/L, a body mass index (BMI) 30 kg/m2 
and a blood pressure 140/90 mmHg. They had no past 
history of heart, lung, kidney, endocrine, or liver disease and 
were not taking any medication. The protocol was approved 
by the Ethics Committee at our institution, and carried out in 
accordance with the principles of the Declaration of Helsinki 
as revised in 2000. Informed written consent was obtained 
from all subjects.
Our diabetic patients were routinely screened for 
macro- and microangiopathy (history of coronary heart 
disease, stroke or claudication, examination of carotid and 
peripheral arteries, and eye funduscopy by an ophthalmolo-
gist). In presence of 2 or more risk factors in addition to 
diabetes, a myocardial radionuclide scintigraphy or a stress 
echocardiography was performed (Consensus Development 
Conference on Insulin Resistance 1998). This was followed 
by a coronarography if required. Coronary heart disease was 
considered present if any one of the following criteria was 
met: history of transmural myocardial infarction, history of 
coronary angioplasty, history of coronary bypass surgery, 
positive evidence for coronary artery disease on an exercise 
tolerance test, a stress echocardiogram, a myocardial 
scintigraphy, or a coronary angiogram. Ultrasonic exami-
nations of carotid and peripheral arteries were obtained 
where appropriate. Diabetic nephropathy was deﬁ  ned as an 
albumin/creatinine ratio 2 mg/mmol in a morning urine 
spot (Gerstein et al 2001; Jermendy et al 2001). Plasma levels 
of brain natriuretic peptide have been measured in the same 
population of diabetics and controls, and the results previ-
ously published (Beer et al 2005).
Protocol
All participants were studied on 2 mornings, after an over-
night fast. The interval between the two sessions ranged 
from 1 to 14 days. On each study day the participants were 
asked to report at our research facility at 07.30, and were left 
to rest on a bed. They were not allowed to drink beverages 
containing caffeine, xanthine, or alcohol and were asked to 
abstain from smoking. The investigations were carried out 
in a quiet room with air conditioning. Ambient temperature 
was systematically measured.
Session 1: After a 30-minute resting period a venous 
cannula was inserted into an antecubital vein for blood 
sampling. This was done without the use of a tourniquet to 
avoid the activation of the coagulation cascade. A 10-mL 
blood sample was ﬁ  rst collected in a prechilled sodium citrate-
coated tube for determining circulating levels of PAI-1, vWF, 
tPA, f-TFPI, and s-TM. After centrifugation at 4°C, the 
plasma was stored at −80°C. An additional 10-mL blood 
sample was drawn in an heparinized tube for measurement 
of plasma, creatinine, total cholesterol, HDL-cholesterol, 
LDL-cholesterol, and triglyceride concentrations.
Session 2: The outline of the study protocol is illustrated 
in Figure 1. On arrival a venous cannula was inserted in 
an antecubital vein and a 10-mL blood sample collected 
in a heparinized tube for measurement of plasma glucose, 
and insulin concentrations. Forearm skin temperature was 
assessed using a cutaneous probe (G. Mettraux, Crissier, 
Switzerland). Blood pressure and heart rate were mea-
sured in supine position using an automated oscillometric 
device (Datascope Accutor 1A, MS Cardio-Medical, Brun-
nen, Switzerland). At 08:00 the participants received a 
standard breakfast containing 75 g carbohydrates and 40 g Vascular Health and Risk Management 2008:4(6) 1451
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fat. Pulse wave velocity was determined between 08:15 
and 09:00. The hyperemic responses to local heating of 
the forearm skin were then assessed, between 09:00 and 
09:30. This was followed, between 10:00 to 11:00, by the 
measurement of the cutaneous microvascular responses to 
iontophorized (Ach and SNP), as well as to the transient 
interruption of forearm circulation (reactive hyperemia, 
RH). Blood sampling (10 mL) was repeated at the end of 
the session for determination of plasma glucose and insulin 
concentrations.
Measurement of pulse wave velocity 
(PWV)
The transmission velocity of the pulse pressure wave between 
the right carotid on one hand and the right femoral and radial 
arteries on the other hand was assessed using a validated, 
automatic device (Complior Artech Medicla) (Asmar et al 
1995). The distance between the recording sites was deter-
mined with a tape-measure over the surface of the body. 
PWV was expressed in meters/sec.
Measurement of skin blood ﬂ  ow
A laser-Doppler imager (Moor Instruments, Axminister, UK) 
was used to measure skin blood ﬂ  ow, as described previously 
(Kubli et al 2000). This device allows the scanning of a region 
of interest, with no skin contact. The distance traveled by the 
incident laser beam from the laser aperture to the skin was 
set at 41 cm. The total ﬂ  ow is expressed in perfusion units 
(PU) according to the principle of laser-Doppler ﬂ  owmetry. 
The sites chosen for the measurements were located on the 
proximal anterior face of the right forearm and were selected 
so as to exclude visible veins.
Response of skin blood ﬂ  ow to local heating
Two stainless steel, temperature-controlled, ring-shaped 
chambers with inner diameter, outer diameter, and thickness of 
8, 25, and 8 mm, respectively, were afﬁ  xed to the forearm skin 
with double-sided tape, ﬁ  lled to the rim with deonized water and 
overlaid with a transparent glass coverslip (Golay et al 2004). 
The skin underneath the coverslip and water was thus accessible 
to laser Doppler imaging, was programmed to repetitively scan 
the area comprising both chambers every 30 seconds.
The chambers were connected to analog temperature 
controllers with adjustable set-point. Their temperature was 
set at 34°C until a stable blood ﬂ  ow reading was obtained, then 
raised in 60 seconds to 37°C in one chamber and 41°C in the 
other, then maintained at this level for the next 11 minutes.
Response to iontophoretically applied Ach and SNP
Iontophoresis is a method of noninvasive transfer of charged 
molecules through the skin by means of an externally 
applied electrical current. To follow with laser Doppler 
ﬂ  owmetry, the responses of skin blood ﬂ  ow to iontophoreti-
cally applied Ach and SNP, we constructed a ring-shaped 
chamber (10 mm internal diameter) in black neoprene 
fitted on the inside with an annular copper electrode 
connected to an iontophoresis controller (MIC1-e; Moor 
Instruments, Axminster, United Kingdom). The chamber 
was afﬁ  xed to the skin with double-sided tape and ﬁ  lled to 
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Figure 1 Outline of the study protocol.
Abbreviations: Ach, acetylcholine; SNP, sodium nitroprusside.Vascular Health and Risk Management 2008:4(6) 1452
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the rim with a solution of either 1% Ach or 0.1% SNP in 
deionized water. The drug solutions were prepared fresh 
on each day (Ach, Sigma Chemie, Buchs, Switzerland; 
SNP, Schwarz Pharma, Aubonne, Switzerland). To avoid 
artifacts generated at the air – liquid interface, the chamber 
was covered with a thin, clear glass lid, with care taken to 
avoid trapping any bubbles underneath. The iontophoresis 
controller was also connected to an indifferent electro-
cardiograph electrode placed on the wrist. Polarity was 
adapted to the electric charge of the vasoactive molecule 
(chamber positive for Ach and negative for SNP). For test-
ing Ach, 3 different doses of current charge density (1.4, 
7, and 28 mC/cm2) were administered, each in a pulsed 
fashion over 7 minutes, with 2 minutes interposed between 
each dose. For SNP, the current charge density was 38 
mC (Kubli et al 2000). The skin was pretreated with an 
anesthetic cream (Emla cream 5%, Astra Pharmaceutica 
AG, Dietikon, Switzerland) applied for 1 hour under an 
occlusive dressing (Tegaderm, 3M Health Care Ltd, UK), 
in order to prevent current-induced, axon reﬂ  ex-mediated 
vasodilation (Wardell et al 1993; Berghoff et al 2002).
Reactive hyperemia
Reactive hyperemia (RH) was assessed with the laser-Doppler 
imager in the forearm skin, at a site not exposed to local anes-
thesia. The arterial occlusion was achieved by a pressure cuff 
placed on the arm and inﬂ  ated at a suprasystolic pressure 
(220 mmHg) for 3 minutes.
Laboratory tests
The plasma levels of vWF, PAI-1, tPA, f-TFPI, and s-TM 
were measured using commercially available enzyme-linked 
immunosorbent assays (Diagnostica Stago, Asnières, 
France).
Statistical analysis
Results are presented as means  ±  SD. Three groups of subjects 
(controls, diabetics without any vascular complication, and 
diabetics with microvascular and/or macrovascular compli-
cations) were compared with simple parametric analysis of 
variance. Where justiﬁ  ed by very asymmetric distribution 
not amenable to logarithmic transform, a Kruskall-Wallis 
test was used instead. When the F (or chi-square) value 
was signiﬁ  cant, pairwise comparisons were carried out with 
Dunn’s test or its nonparametric adaptation (Glanz 1992). 
The alpha level of all tests was set at 0.05. All computations 
were performed with the JMP software, version 3.2.2 (SAS 
Institute, Cary, NC, USA).
Results
Characteristics of the study population
The baseline characteristics of the study subjects are 
summarized in Table 1. Diabetic patients were divided 
into 2 subgroups according to the presence (n = 27) or the 
absence of micro- and/or macrovascular complications 
(n = 27). Among the former patients, 9 exhibited microvascular 
complications and 5 macrovascular complications only, 
whereas 13 patients had both types of complications. Body 
mass index (BMI) as well as systolic and diastolic blood 
pressures were signiﬁ  cantly higher in the two groups of 
diabetics than in the controls. Signiﬁ  cant differences in mean 
levels of Hb1Ac, fasting and post-prandial plasma glucose, 
fasting plasma insulin, plasma creatinine, and urinary 
albumin/creatinine ratio were observed between the two 
groups of diabetics. An exercise tolerance test, a coronary 
angiogram, a stress echocardiogram, and a myocardial 
radionuclide scintigraphy were performed in 6, 5, 24, and 
11 patients, respectively. All patients who underwent the 
echocardiographical examination showed an ejection fraction 
above 50%.
Table 2 shows the various treatments received at the time 
of examination. Blockers of the renin-angiotensin system, 
β-blockers, and anti-aggregatory agents were taken sig-
niﬁ  cantly more often in patients with than in those without 
vascular complications.
There was no signiﬁ  cant difference in room and skin 
temperature between the 3 study groups (Table 3).
Measurement of pulse wave velocity 
(Table 3)
Carotid to radial PWV was comparable in the control sub-
jects and in the two groups of diabetics. Diabetic patients 
with vascular complications showed signiﬁ  cantly increased 
values for carotid to femoral PWV compared with both 
control subjects and diabetic patients without vascular 
complications.
Measurement of skin blood ﬂ  ow (Table 3)
No signiﬁ  cant difference in baseline skin blood ﬂ  ow was 
observed between the control subjects and the two groups 
of diabetics regardless of whether the skin had been exposed 
to the anesthetic cream.
Response of skin blood ﬂ  ow to local 
heating (Table 3)
The maximal skin microvascular dilation induced by 
increasing the local temperature to 37°C was of similar Vascular Health and Risk Management 2008:4(6) 1453
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magnitude in the three study groups. However, when the skin 
temperature was increased to 41°C, maximal vasodilation 
was signiﬁ  cantly lower in diabetics than in controls. The two 
diabetic groups did not differ in this respect.
Response to iontophoretically applied Ach and SNP 
(Table 3)
Three different doses of current charge density were 
tested for the iontophoresis of Ach. The peak vasodilatory 
responses to the 1.4 mC/cm2 and 7 mC/cm2 charges were 
comparable in the thee groups. With the highest 28 mC/cm2 
charge, however, a signiﬁ  cant attenuation of the responses 
was observed in the two groups of diabetics compared 
with controls. The responses were equally blunted in the 
diabetics with and without vascular complications. The 
peak responses to iontophorized SNP were signiﬁ  cantly 
attenuated in the two groups of diabetes, with no differ-
ence, however in the presence and the absence of vascular 
complications.
Reactive hyperemia (Table 3)
The peak hyperemic response was signiﬁ  cantly lower in 
diabetics than in controls, to a similar extent in patients with 
and without vascular complications.
Laboratory tests (Table 4)
In diabetics without complications, the plasma levels 
of PAI-1 and t-PA were elevated to the same extent as in 
those with complications, whereas the levels of the three 
other markers were normal. In diabetic patients with vascular 
complications, the plasma concentrations of all hemostatic 
endothelial cell markers were signiﬁ  cantly increased com-
pared with control subjects.
Discussion
Type 2 diabetes mellitus is becoming increasingly prevalent 
in both developing and industrialized countries, representing 
therefore a leading cause of health disability and health care 
cost (Murray and Lopez 1996; Amos et al 1997). NIDDM is 
Table 1 Characteristics of study participants
Controls Diabetics
without vascular 
complications
with vascular 
complications
Number of subjects 38 27 27
Duration of diabetes (years) – 6.4 ± 6.2 10.8 ± 7.8
Age (years) 56.0 ± 11.1 54.4 ± 7.7 57.9 ± 7.0
Sex (M/F) 25/13 16/11 22/5
Body mass index (kg/m2) 23.0 ± 2.5 30.4 ± 4.8b 31.4 ± 5.4b
Waist to hip ratio 0.92 ± 0.07 1.01 ± 0.05b 1.04 ± 0.08b
Blood pressure, systolic (mmHg) 117 ± 10 133 ± 17b 142 ± 16b
Blood pressure, diastolic (mmHg) 68 ± 8 78 ± 11b 82 ± 9b
Smoking (pack-years) 1.7 ± 7.2 9.7 ± 23.0a 8.5 ± 13.5a
Plasma glucose, fasting (mM) 4.8 ± 0.5 7.0 ± 1.6b 8.4 ± 2.2bc
Plasma glucose, post-prandial (mM) 5.1 ± 0.9 12.4 ± 2.4b 14.2 ± 2.6bc
Plasma insulin (mU/L)
 fasting 10.9 ± 5.3 23.5 ± 13.2b 35.4 ± 21.7bc
 post-prandial 40.5 ± 23.6 79.4 ± 50.7b 82.2 ± 48.8b
HOMA-IR index 2.3 ± 1.3 7.5 ± 5.2b 13.5 ± 9.7bc
HbA1c (%) NA 7.3 ± 1.1 8.2 ± 1.3c
HDL-cholesterol (mM) 1.62 ± 0.34 1.29 ± 0.36b 1.30 ± 0.30b
LDL-cholesterol (mM) 2.96 ± 0.89 2.85 ± 0.71 2.75 ± 0.87
Triglycerides (mM) 0.94 ± 0.47 1.87 ± 0.80b 2.09 ± 1.92b
Plasma creatinine (μM) 89 ± 10 87 ± 15 104 ± 26bc
Urine albumin/creatinine ratioa 0.6 ± 0.5 0.8 ± 0.6 32.4 ± 83.9bc
Notes: Means ± SD. NA, not available.
Statistical analysis: one way parametric ANOVA except for smoking (Kruskall-Wallis non parametric ANOVA).
ap  0.05 vs controls; bp  0.01 vs controls; cp  0.01 diabetics with vs diabetics without vascular complications.Vascular Health and Risk Management 2008:4(6) 1454
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a strong risk factor not only for nephropathy and end stage 
renal failure, but also for all manifestations of atherosclerotic 
disease (Nathan 1993). Most patients with NIDDM die from 
cardiovascular complications (Laasko and Lehto 1997), 
which can be explained by the fact that NIDDM is frequently 
associated with other risk factors such as hypertension, 
central obesity, hyperinsulinemia, and dyslipidemia, the last 
named being characterized mainly by elevated serum total 
triglycerides and low HDL cholesterol, ie, components of 
the metabolic syndrome (Reaven et al 1996; Pyorala et al 
2000; Waeber et al 2001). Not surprisingly most of our 
patients treated for NIDDM received also medications for 
high blood pressure and dyslipidemia (Table 2). Of note also 
is the fact that our patients, whether or not they had detect-
able vascular complications, had increased waist to hip ratio, 
plasma insulin, glucose and triglyceride levels, and decreased 
plasma HDL cholesterol levels compared with age- and 
sex-matched healthy controls (Table 1). The patients with 
Table 2 Number of patients (%) on various therapies
Diabetics without 
vascular complications
Diabetics with 
vascular complications
Insulin 13 (48%) 19 (70%) NSa
Oral antidiabetics 19 (70%) 15 (56%) NS
ACE-I or AT1-receptor blocker 14 (52%) 21 (78%) 0.05
β-blocker 0 12 (44%) 0.001
Diuretic 8 (30%) 13 (48%) NS
Calcium antagonist 7 (26%) 9 (33%) NS
Statin 10 (37%) 16 (59%) NS
Anti-aggregatory agents 9 (33%) 24 (89%) 0.001
anot signiﬁ  cant
Abbreviation: ACE-I, angiotensin converting enzyme inhibitor.
Table 3 Pulse wave velocity and microvascular skin blood ﬂ  ow responses in diabetic patients with and without vascular complications 
compared with control subjects (means ± SD)
Controls Diabetics
(n = 38) without complications (n = 27) with complications (n = 27)
Room temperature (°C) 24.0 ± 0.8 24.3 ± 1.1 24.1 ± 0.7
Skin temperature (°C) 32.7 ± 1.1 32.4 ± 1.2 32.8 ± 1.0
Baseline skin blood ﬂ  ow (PU)
 anesthetized  skin 60 ± 13 60 ± 10 63 ± 13
 unanesthetized  skin 89 ± 28 74 ± 20 89 ± 30
Pulse wave velocity (m/sec)
 carotid-femoral  artery 9.4 ± 2.2 9.9 ± 1.8 11.8 ± 2.2b,c
 carotid-radial  artery 10.2 ± 1.9 9.8 ± 1.7 10.0 ± 0.9
Maximal response to local 
heating (PU)
 37°C 52 ± 45 54 ± 41 56 ± 40
 41°C 322 ± 130 257 ± 111a 242 ± 112a
Maximal response to Ach (PU)
 1.4  mC/cm2 229 ± 119 211 ± 139 163 ± 94
 7.0  mC/cm2 362 ± 89 317 ± 115 301 ± 115
 28.0  mC/cm2 395 ± 94 345 ± 99a 337 ± 102a
Maximal response to SNP (PU) 326 ± 80 274 ± 86b 255 ± 65b
Maximal RH (PU) 183 ± 67 136 ± 55a 134 ± 69a
Analysis with one way parametric ANOVA
ap  0.05 vs controls; bp  0.01 vs controls; cp  0.01 vs diabetics without complications.
Abbreviations: Ach, acetylcholine; PU, perfusion units; RH, reactive hyperemia; SNP, sodium nitroprusside.Vascular Health and Risk Management 2008:4(6) 1455
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vascular complications showed signiﬁ  cantly higher plasma 
glucose, insulin, and HbA1c levels, as well as signiﬁ  cantly 
higher systolic blood pressure than patients without vascular 
complications. These differences were seen despite a very 
similar pattern of drug prescriptions in the two groups, except 
a substantially greater proportion of patients on antiplatelet 
therapy among individuals with vascular complications 
(Table 2). The poorer glucose and blood pressure control 
achieved might have accelerated the atherosclerotic vascular 
disease observed in the latter patients. Whether the presence 
of vascular complications made our patients with NIDDM 
less responsive to antihypertensive therapy is another pos-
sibility to be considered.
Impaired endothelial function, as reﬂ  ected by a decreased 
endothelium-dependent vasodilation, is a hallmark of vascu-
lar disease states (Brunner et al 2005). A common denomina-
tor to all cardiovascular risk factors is an increased oxidative 
stress, resulting in the scavenging of NO, the potent relax-
ing factor released by the endothelium (Waeber and Feihl 
2005; Feletou and Vanhoutte 2006. This has been repeatedly 
documented in patients with NIDDM (Calles-Escandon and 
Cipolla 2001; Ding and Triggle 2005). Endothelial dysfunc-
tion refers usually to a blunted vasodilatory response to Ach, 
which releases NO from the endothelium, while the vaso-
relaxant activity of SNP or nitroglycerin, which act as NO 
donors in vascular muscle cells, is maintained (Deanﬁ  eld et al 
2005). Another way of testing endothelial function is to assess 
the ﬂ  ow-mediated vasodilation, ie, the vasodilation occur-
ring after transient occlusion of the circulation (Anderson 
1999; Deanﬁ  eld et al 2005). Still another means to evaluate 
endothelium function in humans is to study the vasodilation 
induced by local skin heating (Kellogg et al 1999).
Both the endothelium-dependent and -independent 
blood ﬂ  ow responses (measured using venous occlusion 
plethysmography or ultrasonography) have been reported 
to be attenuated in the forearm circulation of patients with 
NIDDM (Zenere et al 1995; Williams et al 1996; Hogikyan 
et al 1998; Natali et al 2006). In three of these studies, hyper-
tensive and dyslipidemic patients were excluded (Zenere et al 
1995; Williams et al 1996; Hogikyan et al 1998), whereas in 
the fourth, 40% and 10% of patients had hypertension (either 
treated or untreated) or dyslipidemia (treated with a ﬁ  brate), 
respectively (Natali et al 2006). Notably, in Williams et al 
(1996) study, measurements were performed after admin-
istration of aspirin to inhibit the endogenous production of 
vasoactive prostanoids from the endothelium. Impaired vaso-
dilatory responses to Ach and SNP have also been reported 
in the skin microvasculature of type 2 diabetics (Morris et al 
1995; Lim et al 1999; Caballero et al 1999. Ach and SNP 
were applied transcutaneously by iontophoresis and skin 
blood ﬂ  ow changes measured by laser Doppler imaging. 
Patients receiving blood pressure- or lipid-lowering drugs 
were excluded. We made similar observations in the pres-
ent investigation, as both the Ach and SNP responses were 
blunted in the presence of NIDDM. It has to be stressed 
that most of our patients were taking not only antidiabetic 
medications, but also blood pressure- and lipid-lowering 
agents, as well as anti-aggregatory drugs. The need for this 
polypharmacy in high risk patients with NIDDM has been 
well documented recently (American Diabetes Association 
2001; Waeber et al 2001). An original aspect of our inves-
tigation deals therefore with the ﬁ  nding of a persistently 
impaired microvascular reactivity in type 2 diabetes despite 
efforts directed to control all traditional cardiovascular risk 
factors. Also, blockers of the renin-angiotensin system and 
statins were the treatments of choice in our patients, which 
corresponds to the current recommendations for the pharma-
cological management of hypertension and dyslipidemia in 
Table 4 Plasma concentrations of hemostatic endothelial cell markers in diabetic patients with and without vascular complications 
compared with control subjects (means ± SD)
Controls Diabetics
(n = 38) without complications n = 27) with complications n = 27)
PAI-1 (ng/mL) 13.7 ± 7.5 51.1 ± 37b 50.0 ± 40.4b
tPA (ng/mL) 6.2 ± 4.1 10.9 ± 4.4b 10.5 ± 4.4b
vWF (IU/dL) 136 ± 48 145 ± 50 180 ± 65bc
f-TFPI (ng/mL) 7.6 ± 3.9 7.8 ± 2.5 9.6 ± 2.5ac
s-TM (ng/mL) 56.8 ± 30.5 53.4 ± 16 77.1 ± 46.7ac
Statistical analysis: one way parametric ANOVA except for PAI-1 (Kruskall Wallis non parametric ANOVA)
ap  0.05 vs controls; bp  0.01 vs controls; cp  0.05 vs diabetics without complications.
Abbreviations: PAI-1, plasminogen activator inhibitor-1; vWF, von Willebrand factor; tPA, tissue plasminogen activator; f-TFPI, free tissue pathway factor inhibitor; s-TM, 
soluble form of thrombomodulin.Vascular Health and Risk Management 2008:4(6) 1456
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patients with NIDDM (American Diabetes Association 2001; 
Waeber et al 2001, 2003; European Society of Hypertension 
2003). The lack of normalization of skin microvascular 
reactivity in our patients might have been expected since 
impaired responses to iontophoretically applied Ach and 
SNP have been reported in subjects with impaired glucose 
tolerance or increased fasting glucose, already before the 
development of established type 2 diabetes (Caballero et al 
1999; Vehkavaara et al 1999).
In addition to the reduced vasodilatory response to ionto-
phorized Ach and SNP, we observed a signiﬁ  cant attenuation 
of the hyperemia caused by local heating of the skin. This is in 
agreement with the previous experience of other investigators 
(Vinik et al 2001). Of note is that the abnormal skin response 
to local heating may reﬂ  ect not only endothelial dysfunction, 
but also the impaired reactivity to nociceptive stimulation 
and the alterations in neuronal release of vasoactive peptides 
encountered in type 2 diabetes (Stansberry et al 1999; Vinik 
et al 2001). Interestingly, the limited microvascular vasodi-
lation triggered by raising the skin temperature had already 
been observed in patients at risk of developing NIDDM, as 
manifested by elevated plasma glucose concentrations still 
below the diabetic range (Jaap et al 1994, 1997).
The last method we used to explore the endothelial 
function of the skin forearm microcirculation was the 
measurement of the flow-mediated vasodilatory capac-
ity, done by assessing the reactive hyperemia that occurs 
after the release of a transient interruption of the circulation 
in the brachial artery. A blunted response was evidenced 
in the diabetics, as expected from previous observations of 
brachial artery diameter changes during the post-ischemic 
period (Caballero et al 1999).
All methods we used for endothelial function testing 
showed an impaired reactivity of skin microcirculation. Our 
diabetic patients were subdivided in 2 groups according to 
the presence or absence of overt micro- and/or macrovascular 
complications. It was hypothesized that endothelial function 
would be altered to a greater degree in patients with manifest 
vascular damage. This was, however, not the case: there was 
no way to discriminate between patients with and without 
vascular complications based on any of the functional mark-
ers that were measured. By contrast, PWV, which is known 
to closely reﬂ  ect arterial thickness (Laurent et al 2006), was 
on average higher in patients with than in those without 
vascular complications, while no difference was detected 
between the latter patients and control subjects. Increased 
arterial stiffness might occur before the onset of NIDDM 
(Henry et al 2003) and has an independent predictive value 
for mortality already at the stage of glucose intolerance 
(Cruickshank et al 2002). Among our diabetic patients, only 
those with clinical micro- and/or macrovascular disease 
exhibited higher PWV in comparison with control subjects. 
In theory, functional alterations of the endothelium should 
occur before structural changes of the arterial wall. Such a 
sequence in the atherosclerotic process could still be detected 
in our patients, even if they took a number of medications 
for controlling hyperglycemia, high blood pressure and/or 
dyslipidemia.
The endothelium is perturbed at all stages of atherogenesis: 
functional abnormalities are seen early during the course of 
the arterial wall disease, which is followed by a progres-
sive injury of endothelial cells as a result of the underlying 
inﬂ  ammatory process and the development of a prothrom-
botic state (Ross 1999; Libby and Simon 2001). The con-
cept of “vulnerable blood” has been proposed to reﬂ  ect the 
hypercoagulability associated with atherosclerosis and the 
predominant release of procoagulant factors occurring which 
characterizes this condition (Naghavi et al 2003). Increased 
circulating levels of vWF, PAI-1, t-PA, TFPI, and s-TM have 
been reported in patients with NIDDM (Collier et al 1992; 
McGill et al 1994; Bagg et al 2001; Aso et al 2002; Leurs 
et al 2002; Rigla et al 2006). In our study, plasma concen-
trations of all these markers of endothelial suffering were 
signiﬁ  cantly higher in patients with vascular complications 
than in control subjects. In the absence of vascular compli-
cations, however, only plasma t-PA and PAI-1 levels were 
signiﬁ  cantly increased compared with those in non-diabetic 
controls. Notably, the presence of vascular or renal complica-
tions has been found in relation to an increased propensity 
to develop coagulation and ﬁ  brinolysis abnormalities (Kario 
et al 1995; Yano et al 2003; Erem et al 2005). Our ﬁ  ndings are 
relevant as they show that endothelial dysfunction in NIDDM 
is not necessarily accompanied by a clustering of hemostatic 
abnormalities, as would be expected if endothelial cells were 
damaged. The fact that most of our patients received medica-
tions known to have a protective action on the endothelium 
might have contributed to this situation.
As a ﬁ  nal and practical note, the apparent progression 
seen in our data from normal plasma levels of vWF, f-TFPI 
and s-TM as well as a normal PWV in diabetics without 
vascular or renal complications, to generalized abnormalities 
of these parameters when such complications are detected, 
suggests that the serial measurement of some, or possibly 
all, of these parameters might be useful for the long term 
monitoring of these patients. Longitudinal studies would be 
required to verify this point.Vascular Health and Risk Management 2008:4(6) 1457
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In summary, our data show that patients with NIDDM, 
when treated as required for coexisting risk factors, exhibit 
endothelial dysfunction at the level of the skin microvascula-
ture. This functional abnormality is associated with increased 
levels of some, but not all, hemostatic markers of endothelial 
damage as long as there is no concurrent micro- and/or mac-
rovascular complication. Further studies are however needed 
to assess whether the control of all cardiovascular risk factors 
allows the prevention and/or the regression of endothelial 
damage in patients with type 2 diabetes.
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